The tool, known as the CNC3 Caregiver Report Questionnaire or CNC3-CRQ, was developed by the Clinical Neuropsychology Collaborative for Childhood Cancers, a multi-institutional group of board-certified neuropsychologists working at leading pediatric cancer centers across North America. Their goal was deceptively simple: to give survivorship clinics a standardized, caregiver-driven screening instrument that could flag children who should be referred for formal neuropsychological services. In the new study, researchers led by Rachel S. Werk of Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine put the questionnaire to the test in a real-world clinical setting, comparing its results directly against the referral recommendations made by the survivorship providers who cared for the children.

The study enrolled 173 childhood cancer survivors seen at a pediatric oncology survivorship clinic, a population that reflected the typical composition of long-term follow-up programs. Roughly 41 percent of the participants had a history of hematologic malignancy, such as leukemia or lymphoma, while 20 percent had survived a central nervous system tumor, the group at highest known risk for cognitive impairment. Parents completed the CNC3-CRQ, answering items that probe multiple neurocognitive domains, and the questionnaire generated both a cumulative screening result and domain-specific scores. Positive scores on the instrument were designed to indicate a need for referral to neuropsychology. Independently, and without knowledge of the questionnaire results, each child’s survivorship provider made a clinical recommendation about whether neuropsychological referral was warranted, creating a natural head-to-head comparison between structured screening and clinical gestalt.

The headline finding was the sheer scale of need the questionnaire uncovered. The CNC3-CRQ recommended neuropsychological referral for 68.2 percent of the survivors screened, a figure that underscores just how common cognitive concerns are in this population and how much unmet demand may be hiding beneath the surface of routine follow-up care. Prior research has documented that even survivors treated with chemotherapy alone, without any radiation to the brain, can show measurable deficits in attention, executive function, and processing speed years after treatment ends. Systematic reviews and meta-analyses have linked these deficits to lower educational attainment, reduced employment, and financial hardship in adulthood, making early identification not merely a clinical nicety but a matter of lifelong equity and opportunity.

Statistically, the convergence between the questionnaire and the clinicians was compelling. Survivors whose providers recommended neuropsychological referral had dramatically higher odds of a positive cumulative screen on the CNC3-CRQ, with an odds ratio of 13.2 and a 95 percent confidence interval spanning 3.76 to 52.1, a result significant at p less than 0.001. In plain terms, when an experienced oncology provider felt a child needed neuropsychological evaluation, the parent questionnaire very often agreed. The relationship held across every neurocognitive domain the instrument measures: parental level of concern and the percentage of symptoms endorsed were significantly and positively associated with provider recommendations in each domain. This domain-by-domain agreement matters because neuropsychological referral decisions are rarely about a single global score; clinicians weigh specific patterns, such as whether a child struggles primarily with working memory, language, or behavioral regulation.

One of the study’s most revealing analyses examined what actually drove providers’ referral decisions. When the researchers asked providers to state their specific reasons for recommending neuropsychology, reported parent or caregiver concern emerged as a key factor, and it was significantly associated with a positive score in the questionnaire’s Executive Functions: Behavior domain, with an odds ratio of 2.45, a 95 percent confidence interval of 1.06 to 5.95, and p less than 0.05. This finding highlights a subtle but important truth about pediatric survivorship care: parents are often the first to notice that something has changed in their child’s ability to organize homework, control impulses, or navigate social situations. A well-designed caregiver-report instrument effectively formalizes and quantifies that parental radar, converting it into data that can trigger timely evaluation rather than waiting for problems to escalate.

The convergence observed in this study is what psychometricians call convergent validity, the degree to which a new instrument agrees with an established criterion. Here the criterion was the accumulated clinical judgment of oncology providers who specialize in the care of childhood cancer survivors, providers who see the late effects of therapy every day. Achieving an odds ratio above 13 for the cumulative screen suggests the questionnaire is not merely duplicating generic developmental checklists but is genuinely tuned to the neurocognitive signature of pediatric cancer treatment. The instrument’s lineage reflects this specificity: it builds on earlier work by Jin-Shei Lai and colleagues, who developed parent-report cognitive function item banks using item response theory and explored their utility in computerized adaptive testing, a modern psychometric approach that allows brief assessments to remain precise across a wide range of ability levels.

Why does a screening tool like this matter so much? Comprehensive neuropsychological assessment is the gold standard for characterizing cognitive late effects, but it is a scarce resource. Board-certified pediatric neuropsychologists are concentrated in major academic centers, and studies have documented demographic, medical, and neighborhood barriers that prevent many children, particularly those from underserved communities, from ever reaching these services. Professional guidelines, including the Children’s Oncology Group’s long-term follow-up guidelines and standards of care articulated in pediatric oncology literature, call for monitoring of neuropsychological outcomes, yet surveys show that delivery of psychosocial and cognitive screening remains inconsistent across institutions. A brief parent-report questionnaire requires no specialized equipment, no dedicated testing sessions, and no neuropsychologist to administer, which means it can be embedded into routine survivorship visits even at community-based clinics far from academic hubs.

The study’s authors are careful about what the tool is and is not. The CNC3-CRQ is a screening and decision-support instrument, not a diagnostic test; a positive screen signals the need for comprehensive evaluation, it does not itself establish impairment. And because the comparison criterion was provider recommendation rather than formal neuropsychological testing, the study cannot yet say how the questionnaire performs against full assessment batteries. The researchers also note that the tool may be particularly valuable for providers with less experience identifying neurocognitive late effects, which is precisely the gap that exists in many treatment centers. In this sense, the questionnaire functions less as a replacement for clinical expertise and more as a democratizing force, packaging the pattern-recognition of specialist centers into a form any survivorship program can deploy.

The implications reach well beyond a single clinic. If validated in broader and more diverse populations, caregiver-report screening could become a standard element of long-term follow-up, ensuring that children treated for leukemia in a community hospital receive the same cognitive surveillance as those treated at a comprehensive cancer center. It could also help standardize research, giving multi-site studies a common metric for identifying survivors at risk and measuring the benefits of cognitive rehabilitation interventions. For the families of the roughly 68 percent of survivors the questionnaire flagged in this cohort, the message is equally direct: the concerns they carry home from clinic visits are real, measurable, and now, increasingly, something the health system can act upon systematically. As survival rates for childhood cancer continue to climb past 85 percent, the frontier of pediatric oncology is shifting from curing the disease to protecting the decades of life that follow, and tools like the CNC3-CRQ represent an elegant, low-cost step in that direction.

Subject of Research: Validation of a caregiver-report neuropsychological screening tool for identifying childhood cancer survivors needing neuropsychology referral

Article Title: A comparison of a novel neuropsychological screening tool with provider recommendations among pediatric cancer survivors

Article References: Werk, R. S., Haldipurkar, S. K., Reichek, J. L., Waanders, A. J., Paek, S., Baptiste, S., Lai, J.-S., & Powell, S. K. (2026). A comparison of a novel neuropsychological screening tool with provider recommendations among pediatric cancer survivors. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02136-9

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02136-9

Keywords: childhood cancer survivors, neuropsychological screening, CNC3-CRQ, neurocognitive late effects, cancer survivorship, caregiver report, executive function, pediatric oncology, convergent validity, referral decision support, cognitive impairment, Journal of Cancer Survivorship

The policy landscape the authors describe has transformed rapidly. In 2016, Australia’s National Health and Medical Research Council issued its Statement on Consumer and Community Involvement in Health and Medical Research, formally endorsing the participation of patients and community members in shaping research. Seven years later, the World Health Organization published its Framework on the Meaningful Engagement of People with Lived Experience, extending that logic to a global stage. Taken together, these documents represent an exponential growth in recognition that people who have lived through illness possess knowledge that clinical training alone cannot provide. Yet, as Sansom-Daly and Schilstra point out, even funding bodies can unwittingly entrench the divide, with grant guidelines requiring applicants to apply as either a researcher or a lived experience expert—but never both. The authors describe the resulting predicament in almost existential terms: for researchers whose lived experience is simultaneously a layer in their track record of expertise and a deeply personal endeavour, there is simply no guidance on whether, or how, to weave their survivor identities into their research contributions.

The two authors arrived at this in-between territory by strikingly different routes. Sansom-Daly was diagnosed with an ependymoma, a type of brain tumour, at age 21. Just weeks after finishing cranial radiotherapy, she began her psychology Honours year. During a laboratory lunch, she shared her story—a moment she recalls as both cathartic and uncomfortable. Her professor’s response, however well-intentioned, made her shrink inward: he called her a hero, an inspiration. She remembers wondering whether her diagnosis was bad enough to warrant such admiration, noting she had not even received chemotherapy. Across her research career, she describes feeling like a survivor-by-stealth. Asked repeatedly how she came to study adolescent and young adult cancer, she would pause, deciding how far back to peel the onion. For years she offered a part-truth, attributing her career direction to her experience as a research assistant on projects concerning onco-fertility and young people’s healthcare experiences, keeping her own patient history out of the account.

Her comfort with disclosure evolved only gradually. As a student, she feared that colleagues would misread her focus on young cancer patients’ psychological needs as a personal agenda rather than a scientific one. Looking back with what she calls 2025 eyes, she can see how her story might have added power to her projects—but she is candid about the confounds. She has since completed a PhD and clinical training, published extensively, and been promoted to Associate Professor, and she acknowledges she cannot be certain how much of her recent ease in sharing stems from the privilege and protection of academic status, and how much reflects a genuine cultural shift toward respecting lived experience in 2025. A telling moment arrived recently after a research workshop, when a young adult approached her and asked whether it was true that she was a survivor. She paused, and something clicked into place. Yes, she said, it was.

Schilstra’s trajectory could hardly have been more different. Born in the United States, she was diagnosed with acute lymphoblastic leukaemia at two and a half years old and relapsed at thirteen. Treatment as a teenager shaped much of her career path. Afterward, she became a patient ambassador for the paediatric oncology department where she was treated, supporting its fundraising efforts, and discovered that sharing her story in written and spoken form exponentially increased her confidence in disclosure—she saw firsthand how her experience could produce positive outcomes for the hospital and the patients she cared about. She initially believed becoming a physician was the only way to help other young people with cancer, but treatment-related cognitive effects, including slowed processing speed and memory difficulties, caused her to fail most of her first-year mathematics and science classes. Her academic advisor told her she had little chance of passing the pre-medicine program, so she switched to psychology and found a new mentor: a clinical psychology professor specialising in childhood chronic illness who guided her through a thesis on social support and quality of life in adolescents with chronic illness, and who explicitly encouraged her to leverage her lived experiences in her research.

That mentorship changed the course of her career. In 2017, after moving to Sydney, she joined Professor Claire Wakefield’s team, where her lived experience was welcomed in her job application and actively sought as a source of insight in her research assistant role. Her PhD supervisor, Dr Joanna Fardell, and her co-supervisor, Sansom-Daly, helped her build a meaningful program of work on that foundation. She has since been invited to serve as a lived experience advisor on multiple national and international research projects, steadily building her capacity as a survivor-scientist. Where Sansom-Daly’s early experiences taught her that disclosure carried professional risk, Schilstra’s taught her the opposite: that lived experience, when actively valued by mentors, could be a gateway to research engagement and leadership rather than a liability to be concealed.

The contrast between these two narratives is not merely anecdotal. The authors situate their reflections within an established psycho-oncology literature showing that adolescent and young adult cancer survivors routinely struggle to decide if and how to disclose their survivor identities to peers, colleagues, romantic partners, and new acquaintances. Despite rising survival rates, young survivors continue to face stigma, social anxiety, negative reactions, and uncomfortable responses like the hero framing Sansom-Daly encountered. What the commentary adds is the observation that these identity negotiations are intensified within academic and healthcare settings, where questions of motivation and bias layer new complexity onto the imposter syndrome already common among early-career researchers. Would the influence of lived experience on one’s research be seen as too strong? Might it overshadow professional expertise, introduce perceived bias, and detract from scientific credibility? Without policy guidance, the authors found, the extent to which each of them disclosed was shaped less by principle than by the specific people and opportunities they happened to encounter along the way.

An intriguing generational thread runs through their analysis. With nearly a decade between them in age, the two authors bracketed a major shift in how the research community treats experiential knowledge. Sansom-Daly’s career began before most of that shift, in an era when lived experience seemed relevant only to advocacy and fundraising—she recalls observing a passionate, outspoken young survivor at a workshop and noting the visible discomfort and distancing of the researchers in the room. The lesson she drew was that identifying as a survivor in professional settings would reduce perceived credibility, and that it was safer, and more professionally advantageous, to simply identify as a researcher. Schilstra’s career, by contrast, developed largely alongside the shift, as policies and funders began calling for lived experience engagement in the design, conduct, and even leadership of research. Her advocacy experience translated directly into research opportunities, allowing her to be respected as both survivor and scientist simultaneously.

The authors see a model for change in a neighbouring field. Mental health researchers have begun generating evidence on the value of lived experience research leadership, in which complementary research and experiential expertise are equally valued. That scholarship has prompted difficult self-reflection about the fact that mental health researchers frequently lead projects about lived experience without having any direct experience themselves, and it frames lived experience leadership as a way of rebalancing epistemic disparities stemming from historical failures to fully and equitably include those with lived experience. Cancer research, the authors argue, would benefit from a similar reckoning. But one key ingredient is missing: training and guidance. They call for practical instruction in how to train individuals with lived experience to effectively, ethically, and safely leverage their experience alongside their research expertise—a need they emphasise is especially acute for early-career survivor-scientists who lack the protective shield of a PhD or professorial title.

Beyond culture change, the authors point to methodological tools already available. Embodied research methods, which involve intersectional reflexivity and explicitly acknowledge how social identities shape research interactions, have been shown to enhance research quality and inclusivity, enabling a holistic understanding of complex health phenomena for marginalised and minoritised patients. The deeper demand, however, is conceptual: policy documents and funding structures must move from a binary of researcher versus lived experience expert toward a continuum of expertise, recognising the varied ways that survivors, researchers, and dual survivor-scientists can contribute along that spectrum. The authors’ message is ultimately one of reframing. Lived experience of cancer, they argue, should never undermine the credibility of an academic cancer researcher. With better guidance and genuine cultural change, the secret can become the superpower—enriching the inclusivity, relevance, and quality of cancer research for the next generation of patients and the scientists who once were among them.

Subject of Research: Dual identity navigation among cancer survivor-scientists and the integration of lived experience expertise into cancer research

Article Title: Secret or superpower? A narrative reflection on navigating dual identities as cancer survivors and cancer scientists

Article References: Sansom-Daly, U. M., & Schilstra, C. E. (2026). Secret or superpower? A narrative reflection on navigating dual identities as cancer survivors and cancer scientists. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02110-5

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02110-5

Keywords: cancer survivors, lived experience, psycho-oncology, survivor-scientists, identity disclosure, adolescent and young adult cancer, research policy, mentorship, epistemic expertise, imposter syndrome, research culture, Journal of Cancer Survivorship

The research team, led by investigators at the Fred Hutchinson Cancer Center in Seattle, surveyed 459 cancer survivors who were, on average, eleven years past their initial diagnosis. That long follow-up window is significant. Most studies of financial toxicity in oncology focus on patients in active treatment, when bills are arriving in a torrent. This study instead asked whether the administrative aftermath of cancer persists long into survivorship, and the answer appears to be yes: 46 percent of participants reported experiencing at least one insurance-related administrative burden.

The researchers examined five distinct categories of administrative burden. Prior authorization, the requirement that an insurer approve a treatment before it is delivered, was reported by 33 percent of survivors who had received immunotherapy. Surprise bills, unexpected charges for services patients believed were covered, affected 46 percent of immunotherapy recipients and 33 percent of those who had undergone surgery. Stepped care, in which insurers require patients to try less expensive therapies before approving others, was reported by 26 percent of immunotherapy patients and 17 percent of chemotherapy recipients. Claim denials were reported by 22 percent of chemotherapy patients and 24 percent of those who had received radiation therapy, while out-of-network charges affected 16 percent of surgical patients. All of these associations were statistically significant.

Perhaps the most striking result is what did not predict these burdens. The type of health insurance a survivor had at the time of diagnosis, whether employer-sponsored, public or otherwise, showed no statistically significant association with the likelihood of experiencing administrative burdens. In other words, the paperwork gauntlet appears to cut across the American insurance landscape, afflicting the privately insured and publicly insured alike. This challenges a common assumption that problems with prior authorization and denials are concentrated in particular insurance products or payer categories.

The study also measured financial toxicity across four dimensions, a framework that treats the financial fallout of cancer as a genuine clinical side effect rather than a mere accounting problem. Financial toxicity encompasses out-of-pocket costs, but also the psychological distress of debt, the behavioral changes families make to cope with bills, and the anxiety and depression that money worries generate. Previous research has linked high financial toxicity to worse quality of life, greater psychological distress and even earlier mortality among patients with cancer, making it a target for intervention in its own right.

Here the treatment picture diverged from the burden picture. Survivors who had undergone surgery, chemotherapy or immunotherapy reported significantly more financial coping behaviors than those who had not received those treatments, meaning they had taken concrete steps to manage the financial damage, such as borrowing, cutting expenses or working extra hours. Insurance type mattered in a narrower way: compared with survivors covered by employer- or school-sponsored insurance, those who had purchased their own insurance reported more financial depression, anxiety and coping. Most other insurance types showed no such association.

Why would immunotherapy and chemotherapy carry such heavy administrative loads? The authors point to the mechanics of how these drugs are approved and paid for. Immunotherapies, which have transformed the treatment of melanoma and many other cancers since the first checkpoint inhibitor was approved in 2011, are among the most expensive injectable drugs in medicine, and their costs have continued to climb after launch. Expensive, specialty drugs are precisely the category that insurers police most aggressively with prior authorization requirements, step therapy protocols and utilization review. Chemotherapy, similarly, sits at the intersection of high cost and complex billing, where coding disputes and coverage questions can easily harden into formal denials.

Surgery and radiation therapy carry different risks. Surgical patients in the study were more likely to report surprise bills and out-of-network charges, a pattern consistent with the well-documented problem of ancillary providers, such as anesthesiologists and pathologists, participating in an operation while remaining outside the patient’s insurance network. Radiation oncology has also been identified in prior literature as a field where prior authorization imposes substantial delays and administrative work. The new findings suggest that no major cancer treatment modality is free of administrative risk, even if the specific burden differs by modality.

The implications for survivors and clinicians are considerable. The study’s authors note that immunotherapy and chemotherapy may confer the highest risk of administrative burdens, but that surgery and radiation can also expose patients to them. Because insurance type at diagnosis did not predict burdens, clinicians cannot easily identify which patients will need help simply by looking at their coverage. Instead, the treatment received may serve as a better signal, allowing financial navigators and care teams to target screening and assistance toward patients whose treatment plans carry elevated administrative risk. Financial navigation programs, which have shown promising primary outcomes in randomized trials for newly diagnosed patients, may need to extend their reach deeper into survivorship.

The research also contributes to a growing social science literature on administrative burden, the learning, compliance and psychological costs that citizens pay when interacting with state and bureaucratic systems. Applied to health insurance, this framework reframes prior authorizations and denials not as isolated annoyances but as a cumulative tax on patients’ time, attention and emotional reserves, levied on people who are often still recovering from life-threatening illness. With nearly half of long-term survivors in this sample reporting at least one such burden, and with burdens linked to more intensive financial coping, the study suggests that the administrative machinery of American health insurance operates as a persistent, treatment-linked stressor in cancer care, one that persists long after the last infusion or radiation session and that no category of coverage reliably shields patients from.

Subject of Research: Administrative burdens and financial toxicity among cancer survivors by insurance type and treatment received

Article Title: Examination of insurance type and cancer treatments with administrative burdens and financial toxicity in a sample of cancer survivors

Article References: Lu, A. Z., Yi, J. C., Henrikson, N. B., Panattoni, L. E., Lowry, D., Harkey, K., & Jones, S. M. W. (2026). Examination of insurance type and cancer treatments with administrative burdens and financial toxicity in a sample of cancer survivors. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02116-z

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02116-z

Keywords: cancer survivors, financial toxicity, administrative burden, prior authorization, health insurance, immunotherapy, chemotherapy, surprise bills, claim denials, radiation therapy, financial coping, Journal of Cancer Survivorship

The review, conducted by a team of researchers based primarily in Australia and the United States, followed the PRISMA-ScR framework for scoping reviews. The authors searched four major databases—Google Scholar, PsycINFO, PubMed, and EMBASE—for peer-reviewed, English-language publications from 2015 to 2025 that described lived experience involvement going beyond standard consultative or participatory methods. After screening 5,228 records and confirming the lived experience credentials of authors where necessary, only twelve publications met the stringent inclusion criteria. That small yield is itself one of the most telling results: in a decade of intense policy attention on patient and public involvement, credible accounts of people with cancer actually leading research are vanishingly rare.

Geographically, the eligible publications came overwhelmingly from high-income countries, with four from the United Kingdom, three from the United States, two from the Netherlands, and one each from Australia, Sweden, and Switzerland. Nearly all—83 percent—focused on adult cancer, with just two addressing adolescents and young adults, a population that faces distinct survivorship challenges. Most of the included papers were editorials or commentaries rather than empirical studies, and five were original research articles. The majority concentrated on survivorship care, psychosocial experiences, and quality-of-life research rather than on biological, epidemiological, or clinical trial research, suggesting that lived experience leadership, where it exists at all, has been confined largely to the psychosocial end of the cancer research spectrum.

The conceptual picture that emerged was one of a continuum. At the most common end, lived experience leadership was framed as a co-researcher or research partner model, in which an adult with cancer or a caregiver joins the research team with equal membership alongside academic and clinical investigators. But equal membership, the authors note, does not equal authority. In most described initiatives, the responsibilities of lived experience researchers centered on providing feedback on documents drafted by others. When they did lead document development, it was typically limited to public-facing materials related to recruitment and dissemination—never to the research questions themselves, the study methods, or the interpretation of findings. Decision-making authority, in other words, remained with academic investigators without lived experience.

Only four of the twelve publications described what the reviewers considered true lived experience research leadership, meaning that a person with both academic credentials and lived experience of cancer held responsibility for the research questions, the methodology, or the writing of the publication. Two publications invoked the concept of the embodied researcher—a figure who draws deliberately on both lived and academic expertise to lead research rather than serving as a source of consultation alongside principal investigators without lived experience. Crucially, the embodied researcher framework treats experiential knowledge not as something to be bracketed or suppressed in the name of objectivity, but as a reflexively integrated source of empirical insight across every stage of the research process.

Only three publications were led by researchers who identified as having lived experience of cancer, and just one explicitly used the embodied research framing. The review also found that lived experience leadership was nearly absent from article titles, mentioned in all but one case only within methods sections under the familiar umbrellas of patient and public involvement or consumer engagement. Five publications did have a first author with lived experience, and four acknowledged that experience in the text or affiliations, but authorship position alone did not reliably signal substantive leadership in study conceptualization, design, or decision-making. Notably, the review found no examples of research leadership by family members or caregivers of people with cancer, who appeared mainly as minority members of larger advisory groups.

The barrier most consistently cited across the literature was funding. If funding were acquired, publications noted, it could provide salaries or reimbursement of participation costs such as travel and time for lived experience researchers—a basic prerequisite for anyone hoping to lead rather than volunteer intermittently. Enablers included tailored training programs matched to the nature and duration of the leadership role and the research focus, whether psychosocial or biomedical, as well as formal terms of reference or strategy documents that clearly specify the roles, responsibilities, and boundaries of lived experience experts. The authors argue that these practical mechanisms, while necessary, are insufficient without deeper structural change in how research institutions conceptualize expertise.

A provocative thread running through the review concerns the relationship between lived experience and scientific objectivity. The authors push back against the concern that research led by people with lived experience introduces unacceptable subjectivity, pointing out that subjectivity is a universal feature of all scientific inquiry. Every scientist, they argue, enters a study with preconceived notions, disciplinary biases, and social positions that shape how questions are framed, how outcomes are defined, and how findings are interpreted. The critical distinction, supported by established methodological principles, lies in whether subjectivity is left unexamined or rigorously engaged through reflexivity and transparency. By that standard, a researcher who has survived cancer and discloses and reflects on that positionality is arguably on firmer methodological ground than one whose relevant experiences go unacknowledged.

The WHO estimates that one in five people will develop cancer in their lifetime, which implies that a significant portion of the existing cancer research workforce already carries direct or indirect experience of the disease—as patients, survivors, family members, or caregivers. Yet very few cancer researchers report or acknowledge such experience in their scientific outputs, and it remains unclear why the field differs so markedly from mental health research, where an emerging lived experience workforce leads embodied research and where the field has begun confronting academic ableism and the stigma, stress, and disclosure dilemmas that early-career lived experience researchers face.

The review closes with three recommendations. First, the field needs clearer conceptual frameworks and positionality guidance that distinguish academic researchers with lived experience who lead embodied research from part-time or voluntary co-researchers and from advisory panel members. Second, institutions should build a sustainable pipeline of embodied researchers through protected funding, tailored training, mentorship, and equitable remuneration, with genuine leadership defined as authority over agenda setting, methodological decisions, interpretation, and dissemination. Third, journals and funding bodies should strengthen reporting guidelines to require detailed descriptions of leadership structures, decision-making authority, and resourcing, enabling comparability across studies. The authors, all of whom have lived experience of cancer diagnosed in childhood or young adulthood, acknowledge limitations including the English-language restriction and the small team, but they argue the direction is clear: cancer research must move beyond binary distinctions between researchers and patients toward a model that recognizes and empowers those who stand in both worlds, transforming symbolic inclusion into accountable, lived experience–led science.

Subject of Research: Lived experience leadership in academic cancer research

Article Title: Lived experience leadership in cancer research: a scoping review of conceptual definitions, roles, responsibilities, and impacts

Article References: Schilstra, C. E., Glinatsis, A., Emery, M., Zebrack, B., Cheung, C. K., Smith, A., & Sansom-Daly, U. M. (2026). Lived experience leadership in cancer research: a scoping review of conceptual definitions, roles, responsibilities, and impacts. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02119-w

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02119-w

Keywords: cancer research, lived experience, embodied researcher, patient and public involvement, scoping review, research leadership, cancer survivors, co-researchers, psycho-oncology, research methodology, health equity, Journal of Cancer Survivorship